0000000000660880

AUTHOR

Saori Mishima

showing 2 related works from this author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

2021

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It was decided by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual guidelines meeting in March 2021 to adapt the ESMO 2020 guidelines to take into account the ethnic differences associated with the treatment of localised colon cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with localised colon cancer representing the oncological societies of Japan (JSMO), China (CSCO), India (…

medicine.medical_specialtyAsiaColorectal cancerDrug availabilityEthnic grouplocalised colon cancerMedical OncologyScientific evidenceFollow-Up StudieRepublic of KoreaAsian countryMedicineReimbursementColonic NeoplasmPan-Asiantreatmentbusiness.industryHematologyESMOmedicine.diseaseClinical PracticediagnosiOncologyDiagnosis treatmentFamily medicinebusinessguidelineHuman
researchProduct

JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatel…

2020

A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in Japan on 27 October 2019, which comprised experts from the JSCO, the Japanese Society of Medical Oncology (JSMO), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the Taiwan Oncology Society (TOS). The purpose of the meeting was to focus on what we have learnt from both microsatellite instability (MSI)/deficient mismatch repair (dMMR) biomarkers in predicting the efficacy of anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) immunotherapy, and the neurotrophic tyrosine receptor kinase (NTRK) gene fusions in predicting the efficacy of inhibitors o…

0301 basic medicineOncologymedicine.medical_specialtyConsensusTaiwanEntrectinibPembrolizumabMedical Oncology03 medical and health sciences0302 clinical medicineJapanInternal medicineNeoplasmsmedicineHumansIn patientTumor typeSolid tumourClinical Trials as Topicbusiness.industryMicrosatellite instabilityExpert consensusHematologymedicine.diseaseClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisMicrosatellite InstabilitybusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct